HCPCS Code G2083: Billing for >56mg Spravato Administration

G2083 is an HCPCS Level II code that represents a single Spravato treatment session involving a high-dose administration.

The G2083 HCPCS code is used to bill outpatient visits that include the administration of more than 56 mg of esketamine nasal spray (Spravato).

G2083 applies to established patients treated in a REMS-certified clinical setting and bundles physician services, clinical supervision, and the mandatory two-hour observation period into a single billable unit.

Understanding how and when to use HCPCS code G2083 is critical to avoiding claim denials and reimbursement issues.

Official Description of HCPCS Code G2083 

According to the CMS, the official description of G2083 is:

“Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation.”

What Services Are Included in G2083?

G2083 includes all of the following in a single payment:

• Physician or qualified healthcare professional supervision
• Clinical staff time during administration
• Two-hour post-dose observation
• Monitoring for sedation, dissociation, and blood pressure changes
• Medical decision-making related to Spravato treatment

You cannot unbundle or separately bill:

• Prolonged service codes
• Observation codes
• Nursing monitoring codes
• Additional supervision services

What Is the Difference Between G2083 and G2082?

HCPCS Codes G2082 and G2083 are differentiated by the total milligrams of esketamine administered during a single treatment session, which leads to confusion. Here is a comparison table of G2083 vs. G2082:

Comparison Factor	G2082	G2083
Dose Threshold	56 mg or less	More than 56 mg
Typical Dose Billed	28 mg or 56 mg	84 mg
Common Use Case	Initial or lower-dose treatment sessions	Maintenance-phase treatment for treatment-resistant depression
Patient Phase	Early or dose-adjustment phase	Ongoing maintenance phase
Billing Accuracy Impact	Underbilling if used for higher doses	Correct billing for high-dose sessions
Risk if Used Incorrectly	Claim denial or underpayment	Claim denial or incorrect reimbursement

Reimbursement Rates For G2083 (2026)

The national average Medicare reimbursement rate for G2083 in 2026 is approximately $1,356.08. For major private payers, G2083 reimbursement is contract-based and averages around $1,240 among insurers such as BCBS, UHC, Aetna, and Cigna.

Key factors that influence G2083 reimbursement include:

• MAC-specific Medicare fee schedules and locality adjustments
• Facility versus non-facility billing status
• Individual commercial payer contracts
• Documentation and compliance with Spravato REMS requirements

Because both MAC jurisdiction and payer contracts affect payment, you should confirm allowed amounts with your MAC and private payers before billing to ensure accurate reimbursement and avoid payment discrepancies.

Where Can G2083 Be Billed?

G2083 can be billed only in approved outpatient, in-person REMS certified settings, including:

• Physician offices
• Outpatient hospital departments

G2083 cannot be billed for:

• Telehealth services
• Home administration
• Non-REMS-certified locations

The patient must remain on-site for the full observation period.

Supervision and the Two-Hour Observation Requirement

Under the Risk Evaluation and Mitigation Strategy (REMS) program, every Spravato dose requires continuous monitoring for two hours after administration.

G2083 already includes:

• Staff time spent observing the patient
• Monitoring for adverse effects such as sedation or dissociation
• On-site presence of a physician or qualified healthcare professional

You cannot bill prolonged service codes or additional observation codes during this two-hour window.

Can You Bill an E/M Code With G2083?

You should not bill a separate E/M code, such as 99213 or 9921,4 with G2083 on the same date of service because G2083 already includes the professional evaluation and the associated medical decision-making, both of which are bundled into the code.

A separate E/M may only be reported if:

• A significant and unrelated medical condition is evaluated
• Documentation supports the separate service
• The payer allows it under contract terms

Always verify payer-specific rules before billing.

What Documentation Is Required to Bill G2083?

Accurate documentation is essential for claim approval and audit defense in Spravato billing and coding. Your records should include:

• Exact time the esketamine nasal spray was administered
• Start and end times of the two-hour observation period
• Blood pressure readings:
  • Before administration
  • At the one-hour mark
  • At the end of the observation
• Confirmation of provider supervision throughout the visit

Incomplete documentation is a common reason for Spravato claim denials.

Do Payers Require Prior Authorization for G2083?

G2083 does not require prior authorization. Most commercial payers, however, require:

• Prior authorization before treatment initiation
• Documentation of treatment-resistant depression
• Evidence of failed antidepressant trials

Authorization should always be verified before the first session to prevent non-payment.

Common Billing Errors Related to G2083 

Common mistakes include:

• Using G2083 for 56 mg or less
• Billing additional observation or prolonged care codes
• Missing observation time documentation
• Billing E/M services without a clear separation
• Incorrect place of service selection

These errors result in claim denials or post-payment audits.

Best Practices for Billing G2083

A compliant billing workflow for G2083 includes:

1. Verify REMS certification and payer coverage
2. Confirm prior authorization if required
3. Select the correct code based on dosage
4. Ensure two-hour on-site observation
5. Document all required timestamps and vitals
6. Submit one unit of G2083 per visit

Final Words

G2083 is the correct billing code for Spravato sessions involving more than 56 mg of esketamine. It bundles evaluation, clinical supervision, and mandatory monitoring into one outpatient service. Accurate dose selection, complete documentation, and payer verification are essential for compliant reimbursement.

For practices administering esketamine, working with a team experienced in Spravato billing and reimbursement management can significantly reduce denials and payment delays. FC Billing supports providers with authorization validation, code-level accuracy, and payer-specific compliance so Spravato services are billed correctly and paid on time.